Advertisement

Chlorothiazide Oral Suspension

[14 September 2016]

Products Affected - Description

Diuril oral suspension, Valeant
250 mg / 5 mL 237 mL bottle (NDC 65649-0311-12)

Reason for the Shortage

Valeant could not provide a reason for the shortage.1

Available Products

There are no products readily available.

Estimated Resupply Dates

Valeant has chlorothiazide oral suspension (Diuril) on back order, and the company cannot provide an estimated resupply date.1

Implications for Patient Care

Chlorothiazide is a thiazide diuretic frequently used in pediatric patients to manage hypertension or for diuresis.2

Safety

Extemporaneously compounded chlorothiazide suspension may be a potential alternative during this shortage. Ensure appropriate compounding technique.

Alternative Agents & Management

Two publications are available outlining methods for compounding chlorothiazide 50 mg/mL oral suspension.3,4

References

  1. Valeant. Customer Service (personal communications). May 8, June 8, August 10, September 8, October 29, November 16 and 24, December 22, 2015; January 14, February 5, and September 13, 2016.
  2. McEvoy GK, Snow EK, Kester L, Litvak K, Miller J, Welsh OH, eds. AHFS DI (Lexi-Comp Online). Bethesda, MD: American Society of Health-System Pharmacists; 2015.
  3. Allen et al. Chlorothiazide 50 mg/mL oral suspension. International Journal of Pharmaceutical Compounding. 2014;18(4):326.
  4. Chlorothiazide. In: Nahata MC, Pai VB, eds. Pediatric Drug Formulations, 6th edition. Cincinnati, OH: Harvey Whitney Books Company; 2011.

Updated

Updated September 14, 2016 by Elyse A. MacDonald, PharmD, MS, BCPS. Created November 7, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing